{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:04:07Z","timestamp":1789009447144,"version":"build-2803163510"},"reference-count":36,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,12,16]],"date-time":"2016-12-16T00:00:00Z","timestamp":1481846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Peripheral T\u2010cell lymphoma (<jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content>) is a heterogeneous group of aggressive non\u2010Hodgkin lymphomas typically associated with poor prognosis. Most patients with <jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content> receive chemotherapy as first\u2010line treatment, but many experience rapid relapse. For patients with relapsed\/refractory <jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content>, responses to treatment and long\u2010term outcomes tend to worsen with increasing lines of therapy. Romidepsin is a potent class I histone deacetylase inhibitor approved by the <jats:styled-content style=\"fixed-case\">US<\/jats:styled-content> Food and Drug Administration for the treatment of <jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content> in patients who have received \u22651 prior therapy. A pivotal phase 2 trial of romidepsin in patients with relapsed\/refractory <jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content> demonstrated an objective response rate of 25% (33\/130), including 15% with confirmed\/unconfirmed complete response, and a median duration of response of 28\u00a0months. In the analysis presented herein, romidepsin was shown to have similar responses and long\u2010term outcomes in patients with 1, 2, and \u22653 prior lines of treatment, including in patients with disease refractory to the last prior therapy. Although adverse events increased with increasing lines of treatment, the rate of dose modifications and discontinuations due to adverse events was not significantly different. These data support the use of romidepsin as salvage treatment for <jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content> irrespective of the number of prior therapies.<\/jats:p>","DOI":"10.1002\/cam4.939","type":"journal-article","created":{"date-parts":[[2016,12,17]],"date-time":"2016-12-17T12:55:24Z","timestamp":1481979324000},"page":"36-44","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T\u2010cell lymphoma"],"prefix":"10.1002","volume":"6","author":[{"given":"Francine","family":"Foss","sequence":"first","affiliation":[{"name":"Yale Cancer Center  New Haven Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University  Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Miles Prince","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre University of Melbourne  Melbourne, Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubomir","family":"Sokol","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center  Tampa Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Caballero","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Salamanca  Salamanca Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Horwitz","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Coiffier","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,12,16]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e3282ce6f8f"},{"key":"e_1_2_7_3_1","unstructured":"American Cancer Society.2015. Cancer Facts & Figures 2015."},{"key":"e_1_2_7_4_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Non\u2010Hodgkin's Lymphomas. V.3.2016."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134270"},{"key":"e_1_2_7_7_1","article-title":"Comprehensive oncology measures for peripheral t\u2010cell lymphoma treatment (COMPLETE): first detailed report of primary treatment","volume":"120","author":"Foss F. M.","year":"2012","journal-title":"Blood"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-231548"},{"key":"e_1_2_7_9_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.8063","article-title":"Progression\u2010free survival for subsequent relapses in patients with peripheral T\u2010cell lymphoma (PTCL)","volume":"30","author":"Horwitz S. M.","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-3-5"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2133"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.313"},{"key":"e_1_2_7_13_1","unstructured":"ISTODAX (romidepsin) [package insert].2016."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-11"},{"key":"e_1_2_7_16_1","article-title":"Responses to romidepsin by line of therapy in patients with relapsed\/refractory (R\/R) peripheral T\u2010cell lymphoma (PTCL)","volume":"32","author":"Foss F. M.","year":"2014","journal-title":"J.\u00a0Clin. Oncol."},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1306"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2010.06.012"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.112.053132"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm730"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2010.00835.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2095"},{"key":"e_1_2_7_24_1","first-page":"233","article-title":"Electrolyte disorders and arrhythmogenesis","volume":"18","author":"El\u2010Sherif N.","year":"2011","journal-title":"Cardiol. J."},{"key":"e_1_2_7_25_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.4881.4881","article-title":"Pralatrexate reverses the trend to progressive resistance to successive systemic treatment regimens in patients with relapsed\/refractory peripheral T\u2010cell lymphoma (PTCL)","volume":"116","author":"O'Connor O. A.","year":"2010","journal-title":"Blood"},{"key":"e_1_2_7_26_1","article-title":"Pralatrexate reverses the trend to progressive resistance in patients with relapsed\/refractory peripheral T\u2010cell lymphoma (PTCL)","volume":"22","author":"Coiffier B.","year":"2011","journal-title":"Ann. Oncol."},{"key":"e_1_2_7_27_1","unstructured":"BELEODAQ (belinostat) [package insert].2014."},{"key":"e_1_2_7_28_1","unstructured":"ADCETRIS (brentuximab vedotin) [package insert].2016."},{"key":"e_1_2_7_29_1","unstructured":"FOLOTYN (pralatrexate) [package insert].2016."},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2782"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2014.08.001"},{"key":"e_1_2_7_33_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.341.341","article-title":"First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed\/Refractory (R\/R) Peripheral T\u2010Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)","volume":"126","author":"O'Connor O. A.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13400"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2320"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0243-8"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/2050-7771-2-16"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.939","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.939","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T16:14:24Z","timestamp":1696608864000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,16]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1002\/cam4.939"],"URL":"https:\/\/doi.org\/10.1002\/cam4.939","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,16]]},"assertion":[{"value":"2016-07-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-09-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-12-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}